CARVEDILOL EFFECTS ON INSULIN RESISTANCE AS A FACTOR DEFINING CLINICAL EFFECTIVENESS IN METABOLIC SYNDROME

Abstract

In 62 patients with Stage I-II arterial hypertension (AH) and metabolic syndrome (MS), clinical effectiveness and insulin resistance (IR) effects of a non-selective alpha-beta-adrenoblocker carvetrend were investigated, for 16-week carvetrend monotherapy, carvetrend combination with corinfar UNO, or their combination with formin and zorstat. Carvetrend, as monotherapy or combined with corinfar UNO, effectively reduced office and 24-hour monitoring blood pressure levels, regardless of the risk factor number. Carvetrend increased peripheral tissue insulin sensitivity, without affecting carbohydrate and lipid metabolism.

Keywords

• metabolic syndrome
• carvetrend
• 24-hour blood pressure monitoring
• insulin resistance
• sympathetic nervous system